Cover Image
市場調查報告書

DNA診斷的全球市場(產品類型·用途·技術·終端用戶·地區別) - 市場規模,佔有率,全球趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔及預測

Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

出版商 Allied Market Research 商品編碼 316194
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
DNA診斷的全球市場(產品類型·用途·技術·終端用戶·地區別) - 市場規模,佔有率,全球趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔及預測 Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
出版日期: 2014年08月14日 內容資訊: 英文 170 Pages
簡介

DNA診斷是為醫療診斷領域帶來一大改革的尖端手法,對醫療相關人員而言,不僅是適當發現癌症,感染疾病,成肌性障礙等各種疾病,判斷給予適當正確療法的一大助力,在確認臨床診斷的基準,以及胎兒檢診方法上也大有幫助。DNA診斷的概念透過了發現諸多分歧的病因之劃期性人體基因圖譜研究計劃而進化,其全球市場預測今後也將以9.8%的年複合成長率(CAGR)成長,到2020年達到190億美金的規模。技術開發在其開發平台及技術的提升上扮演重要的角色。

本報告以DNA診斷的全球市場為焦點,除了依產品類型,用途,技術,終端用戶、地區別分析、預測今後的轉變之外,更彙整,更彙整發展的推動·阻礙因素,技術研究,用途開發,競爭環境,主要加入企業等相關的最新資訊。

第1章 簡介

  • 報告內容
  • 調查實施的理由
    • 主要優點
    • 主要市場區隔
    • 推薦用戶層
  • 調查方法
    • 二次資訊調查
    • 一次資訊採訪
    • 分析工具及模式

第2章 摘要整理

  • 經營團隊的觀點
  • 今後的市場
    • 穩定成長方案
    • 急速成長方案
    • 負成長方案

第3章 市場概要

  • 市場定義和範圍
  • DNA診斷的生物科技的用途
  • 下一代序列技術的責任
  • 重要發現
    • 影響DNA診斷市場最有效的系數
    • DNA診斷市場有力資金來源
    • DNA診斷市場上成功的重要策略
  • 行政府法規
    • 美國食品藥物管理局(FDA)量身訂做醫療的指南
  • Poter的波特的五力分析
  • 價值鏈分析
    • 主體的活動
    • 支援活動
  • 臨床實驗
  • 專利分析
    • 專利分析 - 地區別
    • 專利分析 - 各領域
  • 市場佔有率分析:2013年
  • 市場動態
    • 推動要素
    • 阻礙因素
    • 機會

第4章 DNA診斷的全球市場 - 產品類別

  • 計量儀器
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測
  • 試劑
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測
  • 軟體及服務
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測

第5章 DNA診斷的全球市場 - 各技術

  • PCR
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測
  • 微陣列
    • 實驗室晶片
    • DNA微陣列
    • 蛋白質微陣列
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測
  • 原位雜合技術
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測
  • 定序技術
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測
  • 質譜分析法
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測
  • 其他
    • 重要市場趨勢
    • 競爭情形
    • 主要的成長系數與商機
    • 市場規模及預測

第6章 DNA診斷的全球市場 - 各用途

  • 癌症診察
    • 前列腺癌症
    • 乳癌
    • 結腸直腸癌症
    • 其他
  • 感染性疾病診察
    • B型肝炎病毒(HBV)
    • C型肝炎病毒(HCV)
    • 後天免疫不全病毒1(HIV)
    • 結核(TB)
    • 沙眼披衣菌及淋菌(CT/NG)
    • 人類乳突病毒(HPV)
    • 抗藥性金黃色葡萄球菌(MRSA)
    • 其他
  • 成肌性障礙診斷
  • 臨床診斷確認
  • 胎兒診察
  • 胚胎著床前診斷
  • 其他

第7章 DNA診斷的全球市場 - 各終端用戶

  • 定點照護
  • 中央研究所及診斷中心
  • 自我診察·成藥

第8章 DNA診斷的全球市場 - 地區別

  • 北美
  • 歐洲
  • 亞太地區
  • 中南美·中東·非洲

第9章 亞太地區的DNA診斷市場分析

  • 市場動態
  • 重要市場趨勢
  • 臨床實驗
  • 行政府法規
  • 地區別企業分析
    • 印度
    • 中國
    • 澳洲
    • 日本

第10章 企業簡介(企業概要,簡述,財務成績,策略性動向及發展,SWOT分析)

  • Sysmex
  • Bayer Diagnostic
  • Roche Diagnostics
  • Abbott Laboratories
  • Cephide Inc.
  • Gen-probe Inc. (Hologic)
  • Illumina, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Johnson and Johnson
  • Novartis
目錄
Product Code: DI 14298

DNA diagnostics is a cutting edge method which is set to revolutionize the field of medical diagnostics. This technique enables medical professionals to identify various diseases, such as cancer, infectious diseases, and myogenic disorders, and to determine the appropriate treatment for the same. It is also used for clinical diagnostic confirmation and in prenatal diagnostics. The concept of DNA diagnostics has evolved via the breakthrough human genome project that resulted in the discovery of various disease-causing agents. The DNA diagnostics market is expected to generate 19 billion by 2020, growing at a CAGR of 9.8% during the analysis period. Technological development has played a major role in improving DNA diagnostic platforms and techniques.

Some of the significant technologies which incorporate DNA diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology and mass spectrometry; these technologies are used for sample preparation, DNA isolation etc. Technological developments, which have led to improvements in these methodologies, drive the growth of the DNA diagnostics market. The use of DNA diagnostic methods in prenatal diagnostics and clinical confirmation has also boosted market growth. The DNA diagnostics market is expected to experience a growth spurt in the foreseeable future. Innovations in product design and technology have prompted doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines. The increased adoption of the personalized medicines approach would positively impact the DNA diagnostics market in the foreseeable future. Next generation sequencing is a powerful tool for decoding a number of human diseases, including various forms of cancer. Next generation sequencing reduces the cost of sequencing and increases the throughput. The optimization of sequencing technology could greatly impact the DNA diagnostics market.

The report breaks the market into segments based on product type, technology, application, end users and geography. Based on product types, the market is segmented into instruments, reagents and service & software. The instruments segment holds the dominant share in the market, due to improved healthcare facilities, availability of user-friendly instruments, its competitive cost structure, reliability, size and the growing demand for it in the DNA diagnostics market. However, the service & software segment is expected to grow at a steady rate in the near future due to technological advancements and the incorporation of information technology in the DNA diagnostics market. There are several technologies used in the DNA diagnostics market; these include PCR, mass spectrometry, sequencing technology, in-situ hybridization and microarrays. PCR holds the dominant share due to its frequent usage in diagnostic procedures such as sample preparation, separation and isolation of DNA from collected samples. The DNA diagnostics market is also segmented based on its application in various diseases such as oncology, infectious diseases and myogenic disorders. The oncology segment leads the market and is followed by infectious diseases due to the rising incidence of these diseases and growing elderly population. In terms of geography, the market is segmented into North America, Asia Pacific, Europe and LAMEA. North America holds the dominant share in the market due to the increased adoption of the DNA diagnostics technology and the high prevalence of chronic and infectious diseases. Companies profiled in the report include Roche Diagnostics, Bayer Diagnostic, Sysmex, Abbott laboratories, Gene-probe Inc., Cephide, Illumina, Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Johnson and Johnson, and Novartis.

KEY BENEFITS

  • An in-depth analysis of various regions would provide a clear understanding of current and future trends so that companies can make region specific plans
  • The report studies the application of next generation sequencing technology and biotechnology and their impact on the DNA diagnostics market
  • A comprehensive analysis of the factors that drive and restrict the growth of the DNA diagnostics market is provided
  • Key regulatory guidelines in various regions which impact the DNA diagnostics market are critically examined
  • A quantitative analysis of the current market and estimations through 2013-2020 are provided to showcase the financial caliber of the DNA diagnostics market
  • Detailed analysis of the Asia-pacific region provides insights that would enable companies to plan their business move strategically
  • Value chain analysis in the report gives a clear understanding of the roles of the stakeholders involved in the supply chain of the DNA diagnostics market

MARKET SEGMENTATION:

The DNA diagnostics market is segmented based on product type, technology, application, end users and geography

MARKET BY PRODUCT TYPE

  • Instruments
  • Reagents
  • Service & Software

MARKET BY TECHNOLOGY

  • PCR
  • Microarray
  • In-situ Hybridization
  • Sequencing Technology
  • Mass Spectrometry
  • Others

MARKET BY APPLICATION

  • Oncology
    • Prostate Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Others
  • Infectious Disease
    • Hepatitis B Virus
    • Hepatitis C Virus
    • HIV
    • TB
    • Chlamydia Trachomatic and Neisseria Gonorrhea (CT/NG)
    • HPV
    • Methiciline Resistant Staphylococcus Aureus (MRSA)
    • Others
  • Myogenic Disorder
  • Clinical Diagnostic Confirmation
  • Prenatal Diagnostics
  • Pre-implantation Diagnostics
  • Others

MARKET BY END USERS

  • Point of Care
  • Diagnostic Center
  • Self Testing/OTC

MARKET BY GEOGRAPHY

  • North America
  • Asia Pacific
  • Europe
  • LAMEA

Table of Contents

CHAPTER 1-INTRODUCTION

  • 1.1. Report Description
  • 1.2. Reason for doing the study
    • 1.2.1. Key Benefits
    • 1.2.2. Key Market Segments
    • 1.2.3. Key Audiences
  • 1.3. Research Methodology
    • 1.3.1. Secondary Research
    • 1.3.2. Primary Research
    • 1.3.3. Analyst tools and models

CHAPTER 2-EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond what to expect by 2025($Million)
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3-MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Application of biotechnology in DNA Diagnostic
  • 3.3. Responsibility of Next-generation Sequencing technologies
  • 3.4. Key Findings
    • 3.4.1. Top Factors Impacting on DNA Diagnostics market
    • 3.4.2. Top Investment Pockets of DNA Diagnostics market
    • 3.4.3. Top winning strategies of DNA Diagnostics market
  • 3.5. Government Regulations
    • 3.5.1. FDA guidelines for personalized medicines
  • 3.6. P orter's Five force Analysis
    • 3.6.1. Bargaining power of suppliers
    • 3.6.2. Bargaining power of Buyers
    • 3.6.3. Threat from new entrants
    • 3.6.4. Threat of Substitute
    • 3.6.5. Competitive Rivalry
  • 3.7. Value chain analysis
    • 3.7.1. Primary Activities
    • 3.7.2. Supportive activities
  • 3.8. Clinical Trials
  • 3.9. Patent Analysis
    • 3.9.1. Patent analysis by geographies(2010-2014)
    • 3.9.2. Patent analysis by sub-segment (2010-2014)
  • 3.10. Market Share Analysis,2013
  • 3.11. Market Dynamics
    • 3.11.1. Drivers
      • 3.11.1.1. Increasing incidences of chronic and infectious diseases
      • 3.11.1.2. Technological Advancements and product modification
      • 3.11.1.3. Increase in popularity personalized medicine approach
    • 3.11.2. Restraints
      • 3.11.2.1. High cost involved in reaseach & development
      • 3.11.2.2. Unclear reimbursement policies&stringent government regulation
    • 3.11.3. Opportunities
      • 3.11.3.1. Technological Development
      • 3.11.3.2. Increasing need of Personalized Medicines

CHAPTER 4-GLOBAL DNA DIAGNOSTICS MARKET BY PRODUCT TYPES

  • 4.1. Instruments
    • 4.1.1. Key market trends
    • 4.1.2. Competitive Scenario
    • 4.1.3. Key growth factors and opportunities
    • 4.1.4. Market size and forecast
  • 4.2. Reagents
    • 4.2.1. Key market trends
    • 4.2.2. Competitive Scenario
    • 4.2.1. Key growth factors and opportunities
    • 4.2.2. Market size and forecast
  • 4.3. Software & Services
    • 4.3.1. Key market trends
    • 4.3.1. Competitive Scenario
    • 4.3.1. Key growth factors and opportunities
    • 4.3.2. Market size and forecast

CHAPTER 5-GLOBAL DNA DIAGNOSTICS MARKET BY TECHNOLOGY, 2013-2020

  • 5.1. PCR
    • 5.1.1. Key market trends
    • 5.1.2. Competitive scenario
    • 5.1.3. Key growth factors and opportunities
    • 5.1.4. Market size and forecast
  • 5.2. Microarrays
    • 5.2.1. Lab on chip
    • 5.2.2. DNA microarray
    • 5.2.3. Protein microarray
    • 5.2.4. Key market trends
    • 5.2.5. Competitive scenario
    • 5.2.6. Key growth factors and opportunities
    • 5.2.7. Market size and forecast
  • 5.3. In situ hybridization
    • 5.3.1. Key market trends
    • 5.3.2. Competitive scenario
    • 5.3.3. Key growth factors and opportunities
    • 5.3.4. Market size and forecast
  • 5.4. Sequencing Technology
    • 5.4.1. Key market trends
    • 5.4.2. Competitive scenario
    • 5.4.3. Key growth factors and opportunities
    • 5.4.4. Market size and forecast
  • 5.5. Mass Spectrometry
    • 5.5.1. Key market trends
    • 5.5.2. Competitive scenario
    • 5.5.3. Key growth factors and opportunities
    • 5.5.4. Market size and forecast
  • 5.6. Others
    • 5.6.1. Key market trends
    • 5.6.2. Competitive scenario
    • 5.6.3. Key growth factors and opportunities
    • 5.6.4. Market size and forecast

CHAPTER 6-GLOBAL DNA DIAGNOSTICS MARKET BY APPLICATIONS, 2013-2020

  • 6.1. Oncology
    • 6.1.1. Prostate Cancer
    • 6.1.2. Breast Cancer
    • 6.1.3. Colorectal Cancer
    • 6.1.4. Others
  • 6.2. Infectious disease testing
    • 6.2.1. Hepatitis B Virus (HBV)
    • 6.2.2. Hepatitis C Virus (HCV)
    • 6.2.3. Human Immunodeficiency Virus (HIV)
    • 6.2.4. Tuberculosis (TB)
    • 6.2.5. Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG)
    • 6.2.6. Human Papillomavirus (HPV)
    • 6.2.7. Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • 6.2.8. Others
  • 6.3. Myogenic disorder diagnosis
  • 6.4. Clinical diagnosis confirmation
  • 6.5. Prenatal diagnosis
  • 6.6. Pre-implantation diagnosis
  • 6.7. Others

CHAPTER 7-GLOBAL DNA DIAGNOSTIC MARKET BY END-USERS, 2013-2020

  • 7.1. Point of Care
  • 7.2. Central Laboratories/Diagnostic Centers
  • 7.3. Self Testing/OTC

CHAPTER 8-GLOBAL DNA DIAGNOSTIC MARKET BY GEOGRAPHY, 2013-2020

  • 8.1. North America
    • 8.1.1. Key market trends
    • 8.1.2. Competitive scenario
    • 8.1.3. Key growth factors and opportunities
    • 8.1.4. Market size and forecast
    • 8.1.5. United States
    • 8.1.6. Canada
    • 8.1.7. Mexico
  • 8.2. Europe
    • 8.2.1. Key market trends
    • 8.2.2. Competitive scenario
    • 8.2.3. Key growth factors and opportunities
    • 8.2.4. Market size and forecast
    • 8.2.5. France
    • 8.2.6. Germany
    • 8.2.7. United Kingdom
    • 8.2.8. Others
  • 8.3. Asia-Pacific
    • 8.3.1. Key market trends
    • 8.3.2. Competitive scenario
    • 8.3.3. Key growth factors and opportunities
    • 8.3.4. Market size and forecast
  • 8.4. LAMEA
    • 8.4.1. Key market trends
    • 8.4.2. Competitive scenario
    • 8.4.3. Key growth factors and opportunities
    • 8.4.4. Market size and forecast
    • 8.4.5. Latin America
    • 8.4.6. Middle East
    • 8.4.7. Africa

CHAPTER 9-ASIA PACIFIC DNA DIAGNOSTIC MARKET ANALYSIS 2013-2020

  • 9.1. Market dynamics
  • 9.2. Key market trends
  • 9.3. Clinical trials
  • 9.4. Government regulations
  • 9.5. Company analysis by region
    • 9.5.1. India
      • 9.5.1.1. Genome Diagnostics Pvt. Ltd.
      • 9.5.1.2. Transasia
      • 9.5.1.3. Dr Reddy's lab
    • 9.5.2. china
    • 9.5.3. Australia
  • 9.5.3.1. Genera biosystems
    • 9.5.4. Japan
  • 9.5.4.1. Sysmex

CHAPTER 10-COMPANY PROFILES

  • 10.1. Sysmex
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial performance
    • 10.1.4. Strategic moves and developments
      • 10.1.4.1. Primary Strategy: product launch
      • 10.1.4.2. secondary Strategy: collaboration and partnership
    • 10.1.5. SWOT analysis
  • 10.2. Bayer Diagnostic
    • 10.2.1. Overview
    • 10.2.2. Company snapshot
    • 10.2.3. Financial performance
    • 10.2.4. Strategic moves and developments
      • 10.2.4.1. Primary Strategy: product launch
    • 10.2.5. SWOT analysis
  • 10.3. Roche Diagnostics
    • 10.3.1. Overview
    • 10.3.2. Company snapshot
    • 10.3.3. Financial performance
    • 10.3.4. Strategic moves and developments
      • 10.3.4.1. Primary Strategies:product launch
      • 10.3.4.2. Secondary Strategy: Collaboration
    • 10.3.5. SWOT analysis
  • 10.4. Abbott Laboratories
    • 10.4.1. Overview
    • 10.4.2. Company snapshot
    • 10.4.3. Financial performance
    • 10.4.4. Strategic moves and developments
      • 10.4.4.1. Primary Strategies: product launch
    • 10.4.5. SWOT analysis
  • 10.5. Cephide Inc.
    • 10.5.1. Overview
    • 10.5.2. Company snapshot
    • 10.5.3. Financial performance
    • 10.5.4. Strategic moves and developments
      • 10.5.4.1. Primary Strategies: partnership and product launch
      • 10.5.4.2. Secondary Strategy: Collaboration
    • 10.5.5. SWOT analysis
  • 10.6. Gen-probe Inc. (Hologic)
    • 10.6.1. Overview
    • 10.6.2. Company snapshot
    • 10.6.3. Financial performance
    • 10.6.4. Strategic moves and developments
      • 10.6.4.1. Primary Strategy: product launch
    • 10.6.5. SWOT analysis
  • 10.7. Illumina, Inc.
    • 10.7.1. Overview
    • 10.7.2. Company snapshot
    • 10.7.3. Financial performance
    • 10.7.4. Strategic moves and developments
      • 10.7.4.1. Primary Strategies: partnership and product launch
    • 10.7.5. SWOT analysis
  • 10.8. Thermo Fisher Scientific
    • 10.8.1. Overview
    • 10.8.2. Company snapshot
    • 10.8.3. Financial performance
    • 10.8.4. Strategic moves and developments
      • 10.8.4.1. Primary Strategies:product launch
      • 10.8.4.2. Secondary Strategy: Collaborationand acquisition
    • 10.8.5. SWOT analysis
  • 10.9. Bio-Rad Laboratories
    • 10.9.1. Overview
    • 10.9.2. Company snapshot
    • 10.9.3. Financial performance
    • 10.9.4. Strategic moves and developments
      • 10.9.4.1. Primary Strategies: product launch
      • 10.9.4.2. Secondary Strategies: Acquistaion
    • 10.9.5. SWOT analysis
  • 10.10. Johnson and Johnson
    • 10.10.1. Overview
    • 10.10.2. Company snapshot
    • 10.10.3. Financial performance
    • 10.10.4. Strategic moves and developments
      • 10.10.4.1. Primary strategies: collaboration
    • 10.10.5. SWOT analysis
  • 10.11. Novartis
    • 10.11.1. Overview
    • 10.11.2. Company snapshot
    • 10.11.3. Financial performance
    • 10.11.4. Strategic moves and developments
      • 10.11.4.1. Primary Strategies: product launch
      • 10.11.4.2. secondary Strategies: collaboration and partnership
    • 10.11.5. SWOT analysis

List of Tables

  • TABLE 1: Dna diagnostic market moderate growth scenario by geography, 2020-2025 ($Million)
  • TABLE 2: Dna diagnostic market rapid growth scenario by geography, 2020-2025 ($Million)
  • TABLE 3: Dna diagnostic market diminishing growth scenario by geography, 2020-2025 ($Million)
  • TABLE 4: Milestone of FDA guidelines for personalized medicines
  • TABLE 5: Clinical trials conducted for DNA diagnostics technologies
  • TABLE 6: Chronic Disease Prevalence
  • TABLE 7: Types of DNA diagnostic devices by technology
  • TABLE 8: Global dna diagnostic market revenue by product types, 2013-2020 ($Million)
  • TABLE 9: Global Instrument dna diagnostic market revenue by geography, 2013-2020 ($Million)
  • TABLE 10: Global reagents dna diagnostic market revenue by geography, 2013-2020 ($Million)
  • TABLE 11: Global software & services dna diagnostic market revenue by geography, 2013-2020 ($Million)
  • TABLE 12: Global dna diagnostic market revenue by technology 2013-2020 ($Million)
  • TABLE 13: Global PCR technology market revenue by geography: 2020-2025 ($Million)
  • TABLE 14: Microarray technology pricing chart
  • TABLE 15: Global Microarray technology market revenue by geography, 2013-2020 ($Million)
  • TABLE 16: In situ hybridization devices pricing chart
  • TABLE 17: Global In situ hybridization technology market revenue by geography, 2013-2020 ($Million)
  • TABLE 18: Global sequencing technology market revenue by market revenue by geography, 2013-2020 ($Million)
  • TABLE 19: laboratory equipment prices
  • TABLE 20: Global mass spectrometry market revenue by geography, 2013-2020 ($Million)
  • TABLE 21: Global other technology market revenue by geography, 2013-2020 ($Million)
  • TABLE 22: Global dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 23: Global oncology dna diagnostic application market revenue by geography, 2013-2020 ($Million)
  • TABLE 24: Global Infectious diseases dna diagnostic application market revenue by geography, 2013-2020 ($Million)
  • TABLE 25: Global Myogenic disorder dna diagnostic application market revenue by geography, 2013-2020 ($Million)
  • TABLE 26: Global Clinical dna diagnostic application market revenue by geography, 2013-2020 ($Million)
  • TABLE 27: Global Prenatal dna diagnostic application market revenue by geography, 2013-2020 ($Million)
  • TABLE 28: Global Per-implantation dna diagnostic application market revenue by geography, 2013-2020 ($Million)
  • TABLE 29: Other dna diagnostic application market revenue by geography, 2013-2020 ($Million)
  • TABLE 30: Global dna diagnostic market revenue by end users: 2013-2020 ($Million)
  • TABLE 31: Global point of care dna diagnostic market revenue by geography, 2013-2020 ($Million)
  • TABLE 32: Global diagnostic center dna diagnostic market revenue by geography, 2013-2020 ($Million)
  • TABLE 33: Global Self testing/OTC dna diagnostic market revenue by geography, 2013-2020 ($Million)
  • TABLE 34: United states dna diagnostics market revenue by application, 2013-2020 ($ million)
  • TABLE 35: Canada dna diagnostic market revenue by application, 2013-2020 ($ million)
  • TABLE 36: Mexico dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 37: France dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 38: Germany dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 39: United kingdom dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 40: Others dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 41: Asia pacific dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 42: lamea dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 43: LAtin america dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 44: Middle east dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 45: Africa dna diagnostic market revenue by application, 2013-2020 ($Million)
  • TABLE 46: Company snapshot of Sysmex
  • TABLE 47: Company snapshot of Bayer Diagnostic
  • TABLE 48: Company snapshot of Roche DIAGNOSTICS
  • TABLE 49: Company snapshot of Abbott Laboratories
  • TABLE 50: Company snapshot Cephide inc
  • TABLE 51: Company snapshot of Gen-probe Inc. (Hologic)
  • TABLE 52: Company snapshot of Illumina, Inc.
  • TABLE 53: Company snapshot of Thermo Fisher Scientific
  • TABLE 54: Company snapshot of Bio-Rad Laboratories
  • TABLE 55: Company snapshot of Johnson & Johnson
  • TABLE 56: Company snapshot of Novartis

List of Figures

  • FIG. 1: Top Factors Impacting on DNA Diagnostics market
  • FIG. 2: Top Investment Pockets of DNA Diagnostics market
  • FIG. 3: Top winning strategies for DNA diagnostic market during 2010-2014
  • FIG. 4: Recent development of DNA diagnostic market by companies (2010-2014)
  • FIG. 5: Top wining strategies by subtype of developments
  • FIG. 6: Porter's Five force Analysis of DNA DIagnostics market
  • FIG. 7: Value chain analysis of Dna diagnostics market
  • FIG. 8: Patent analysis by geographies (2010-2014)
  • FIG. 9: Patent analysis of Sub Segment(2010-2014)
  • FIG. 10: Market share analysis of DNA diagnostics market
  • FIG. 11: Factors affecting the commercial potential of companies developing a molecular diagnostic
  • FIG. 12: Net sales by geographic region (2013)
  • FIG. 13: SWOT analysis of sysmex
  • FIG. 14: Revenue generated
  • FIG. 15: Revenue generation by segments
  • FIG. 16: Swot analysis of Bayer
  • FIG. 17: Net diagnostic sales by geography (2013)
  • FIG. 18: SWOT analysis of roche Diagnostics
  • FIG. 19: Net revenue generation by abbott (2012-2013)
  • FIG. 20: Net revenue generation by segments (2013)
  • FIG. 21: SWOT analysis of abbott LABORATORIES
  • FIG. 22: Net sales by geography (2013)
  • FIG. 23: Net sales by clinical and non clinical market(2013)
  • FIG. 24: SWOT analysis of cepheid inc.
  • FIG. 25: Revenue generated by the company in 2011 and 2012
  • FIG. 26: SWOT analysis of Gen-probe Inc. (Hologic)
  • FIG. 27: Net revenue generation (2012-2013)
  • FIG. 28: SWOT analysis of ILLUMINA, INC.
  • FIG. 29: Net sales by segments (2013)
  • FIG. 30: Revenue generation (2011-2013)
  • FIG. 31: Revenue genetaration by segments (2013)
  • FIG. 32: Swot analysis of Thermo Fisher Scientific
  • FIG. 33: Net revenue generation (2011-2013)
  • FIG. 34: Net sales by segments (2013)
  • FIG. 35: Net sales by geogrephy (2013)
  • FIG. 36: SWOT analysis of bio-rad laboratories
  • FIG. 37: Revenue generation by Segment (2013)
  • FIG. 38: Revenues generation by Geography (2013)
  • FIG. 39: SWOT analysis of johnson & johnson
  • FIG. 40: Net revenue generation by geography (2013)
  • FIG. 41: Net revenue generation by businesses (2013)
  • FIG. 42: SWOT analysis of Novartis
Back to Top